This mechanism has been described in two published case reports of patients treated with BRAF/MEK inhibitor therapy: one patient with papillary thyroid cancer and one patient with non-small cell lung cancer. This evidence concerns the gene MAP2K7 and thyroid gland papillary carcinoma.